Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
March 26, 2020Targovax to present at the 2020 Solebury Trout Virtual Investor Conference today
March 20, 2020Impact of corona virus (COVID-19) on Targovax’s operations
March 11, 2020Targovax ASA: Fourth quarter 2019 results
March 11, 2020Targovax ASA: Annual Report 2019